Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Effective targeting of primary human leukemia using anti-CD123 chimeric antigen receptor engineered T cells

Effective targeting of primary human leukemia using anti-CD123 chimeric antigen receptor engineered T cells

US Patent 11028177 · Granted Jun 8, 2021

Estimated economic value: $23,526,000 ⓘ

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Anti-TCR antibody molecules and uses thereof2025
Chimeric antigen receptor T regulatory cells for the treatment of atherosclerosi2025
Methods of treating cancer using anti-CD137 antibodies2025
Multispecific antibody molecules comprising lambda and kappa light chains2025
Switch costimulatory receptors2025
Chimeric antigen receptors and uses thereof2025
Antibody molecules that bind to NKP30 and uses thereof2025
Multifunctional molecules that bind to T cell related cancer cells and uses ther2025
Compositions and methods for generating a persisting population of T cells usefu2025
Compositions and methods for generating a persisting population of T cells usefu2025
Anti-TCR antibody molecules and uses thereof2025
CD20 therapies, CD22 therapies, and combination therapies with a CD19 chimeric a2025